
GSK announced plans today to spend £1.6 billion on buying Canadian drug maker Bellus Health in a move that will help revitalise the City’s reputation for dealmaking while bringing a potential blockbuster cough treatment to the FTSE 100 company.
The $2 billion shot in the arm for the capital comes after a recent quiet spell for mergers and acquisitions added to worries about its status as a major international M&A venue.